Journal article

Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder

Margaret T Davis, Nicole DellaGiogia, Paul Maruff, Robert H Pietrzak, Irina Esterlis



Intravenous (IV) subanesthetic doses of ketamine have been shown to reduce psychiatric distress in both major depressive (MDD) and posttraumatic stress disorder (PTSD). However, the effect of ketamine on cognitive function in these disorders is not well understood. To address this gap, we examined the effect of a single dose of IV ketamine on cognition in individuals with MDD and/or PTSD relative to healthy controls (HC). Psychiatric (n = 29; 15 PTSD, 14 MDD) and sex- age- and IQ matched HC (n = 29) groups were recruited from the community. A single subanesthetic dose of IV ketamine was administered. Mood and cognitive measures were collected prior to, 2 h and 1 day post-ketamine administrat..

View full abstract

University of Melbourne Researchers


Awarded by VA National Center for PTSD

Funding Acknowledgements

The authors would like to thank the staff of the Yale PET Center for their assistance, and our participants for their time and effort. Drs. Davis, Pietrzak, and Esterlis' work has been funded by the NIMH, Yale Center for Clinical Investigation, Nancy Taylor Foundation, and VA National Center for PTSD. Specific awards relevant to this work are listed here: (1K08MH117351-01 (PI: Davis), K01MH092681 (PI: Esterlis), VA National Center for PTSD (Esterlis; Pietrzak), R01MH104459 (PI:Esterlis).